SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021

被引：82

作者：

Murhekar, Manoj, V ^{[1
]}

Bhatnagar, Tarun ^{[1
]}

Thangaraj, Jeromie Wesley Vivian ^{[1
]}

Saravanakumar, V ^{[1
]}

Kumar, Muthusamy Santhosh ^{[1
]}

Selvaraju, Sriram ^{[2
]}

Rade, Kiran ^{[3
]}

Kumar, C. P. Girish ^{[1
]}

Sabarinathan, R. ^{[1
]}

Turuk, Alka ^{[4
]}

Asthana, Smita ^{[5
]}

Balachandar, Rakesh ^{[6
]}

Bangar, Sampada Dipak ^{[7
]}

Bansal, Avi Kumar ^{[8
]}

Chopra, Vishal ^{[9
]}

Das, Dasarathi ^{[10
]}

Deb, Alok Kumar ^{[11
]}

Devi, Kangjam Rekha ^{[12
]}

Dhikav, Vikas ^{[13
]}

Dwivedi, Gaurav Raj ^{[14
]}

Khan, S. Muhammad Salim ^{[15
]}

Kumar, M. Sunil ^{[16
]}

Laxmaiah, Avula ^{[17
]}

Madhukar, Major ^{[18
]}

Mahapatra, Amarendra ^{[10
]}

Rangaraju, Chethana ^{[19
]}

Turuk, Jyotirmayee ^{[10
]}

Yadav, Rajiv ^{[20
]}

Andhalkar, Rushikesh ^{[2
]}

Arunraj, K. ^{[2
]}

Bharadwaj, Dinesh Kumar ^{[17
]}

Bharti, Pravin ^{[20
]}

Bhattacharya, Debdutta ^{[10
]}

Bhat, Jyothi ^{[20
]}

Chahal, Ashrafjit S. ^{[9
]}

Chakraborty, Debjit ^{[11
]}

Chaudhury, Anshuman ^{[2
]}

Deval, Hirawati ^{[14
]}

Dhatrak, Sarang ^{[6
]}

Dayal, Rakesh ^{[21
]}

Elantamilan, D. ^{[13
]}

Giridharan, Prathiksha ^{[2
]}

Haq, Inaamul ^{[15
]}

Hudda, Ramesh Kumar ^{[13
]}

Jagjeevan, Babu ^{[17
]}

Kalliath, Arshad ^{[16
]}

Kanungo, Srikanta ^{[10
]}

Krishnan, Nivethitha N. ^{[2
]}

Kshatri, Jaya Singh ^{[10
]}

Kumar, Alok ^{[2
]}

机构：

[1] ICMR Natl Inst Epidemiol, Chennai 600077, Tamil Nadu, India

[2] ICMR Natl Inst Res TB, Chennai, Tamil Nadu, India

[3] Who Country Off India, New Delhi, India

[4] Indian Council Med Res, New Delhi, India

[5] ICMR Natl Inst Canc Prevent & Res, Noida, Uttar Pradesh, India

[6] ICMR Natl Inst Occupat Hlth, Ahmadabad, Gujarat, India

[7] ICMR Natl AIDS Res Inst, Pune, Maharashtra, India

[8] ICMR Natl JALMA Inst Leprosy & Other Mycobacteria, Agra, Uttar Pradesh, India

[9] State TB Training & Demonstrat Ctr, Patiala, Punjab, India

[10] ICMR Reg Med Res Ctr, Bhubaneswar, Odisha, India

[11] ICMR Natl Inst Cholera & Enter Dis, Kolkata, W Bengal, India

[12] ICMR Reg Med Res Ctr, Dibrugarh, Assam, India

[13] ICMR Natl Inst Implementat Res Noncommunicable Di, Jodhpur, Rajasthan, India

[14] ICMR Reg Med Res Ctr, Gorakhpur, Uttar Pradesh, India

[15] Govt Med Coll Srinagar, Jammu, Jammu & Kashmir, India

[16] State TB Training & Demonstrat Ctr, Thiruvananthapuram, Kerala, India

[17] ICMR Natl Inst Nutr, Hyderabad, Telangana, India

[18] ICMR Rajendra Mem Res Inst Med Sci, Patna, Bihar, India

[19] Bangalore & Lady Willingdon State TB Ctr, Natl TB Inst, Bengaluru, Karnataka, India

[20] ICMR Natl Inst Res Tribal Hlth, Jabalpur, Madhya Pradesh, India

[21] State TB Training & Demonstrat Ctr, Ranchi, Bihar, India

[22] State TB Off, Hyderabad, Andhra Pradesh, India

[23] State TB Training & Demonstrat Ctr, Raipur, Madhya Pradesh, India

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2021年 / 108卷

关键词：

SARS-CoV-2; COVID-19; IgG; Seroprevalence; India;

D O I：

10.1016/j.ijid.2021.05.040

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: Earlier serosurveys in India revealed seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) of 0.73% in May-June 2020 and 7.1% in August-September 2020. A third serosurvey was conducted between December 2020 and January 2021 to estimate the seroprevalence of SARS-CoV-2 infection among the general population and healthcare workers (HCWs) in India. Methods: The third serosurvey was conducted in the same 70 districts as the first and second serosurveys. For each district, at least 400 individuals aged >10 years from the general population and 100 HCWs from subdistrict-level health facilities were enrolled. Serum samples from the general population were tested for the presence of immunoglobulin G (IgG) antibodies against the nucleocapsid (N) and spike (S1-RBD) proteins of SARS-CoV-2, whereas serum samples from HCWs were tested for anti-S1-RBD. Weighted seroprevalence adjusted for assay characteristics was estimated. Results: Of the 28,598 serum samples from the general population, 4585 (16%) had IgG antibodies against the N protein, 6647 (23.2%) had IgG antibodies against the S1-RBD protein, and 7436 (26%) had IgG antibodies against either the N protein or the S1-RBD protein. Weighted and assay-characteristic adjusted seroprevalence against either of the antibodies was 24.1% [95% confidence interval (CI) 23.0- 25.3%]. Among 7385 HCWs, the seroprevalence of anti-S1-RBD IgG antibodies was 25.6% (95% CI 23.5- 27.8%). Conclusions: Nearly one in four individuals aged >10 years from the general population as well as HCWs in India had been exposed to SARS-CoV-2 by December 2020. (c) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).

引用

页码：145 / 155

页数：11

共 50 条

[41] SARS-CoV-2 Seroprevalence Survey in Grocery Store Workers-Minnesota, 2020-2021
Vachon, Madhura S.
Demmer, Ryan T.
Yendell, Stephanie
Draeger, Kathryn J.
Beebe, Timothy J.
Hedberg, Craig W.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (06)
[42] SARS-CoV-2 seroprevalence in healthcare workers in a tertiary healthcare network in Victoria, Australia
Lau, Jillian Sy
Buntine, Paul
Price, Melanie
Darzins, Peteris
Newnham, Evan
Connell, Ailie
Chean, Roy
Edwards, Glenn
Guy, Stephen
INFECTION DISEASE & HEALTH, 2021, 26 (03) : 208 - 213
[43] Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait
Alfouzan, Wadha
Altawalah, Haya
AlSarraf, Ahmad
Alali, Walid
Al-Fadalah, Talal
Al-Ghimlas, Fahad
Alajmi, Saud
Alajmi, Mubarak
AlRoomi, Ebtehal
Jeragh, Ahlam
Dhar, Rita
VACCINES, 2023, 11 (02)
[44] Seroprevalence of SARS-CoV-2 antibodies among Japanese healthcare workers from 2020 to 2022 as assayed by two commercial kits
Yan Yan
Kaori Saito
Toshio Naito
Kanami Ito
Shuko Nojiri
Yuki Horiuchi
Gautam A. Deshpande
Hirohide Yokokawa
Yoko Tabe
Scientific Reports, 14
[45] Prevalence of SARS-CoV-2 infections among Swedish healthcare workers on duty in December 2023
Aguilera, Katherina
Bladh, Oscar
Marking, Ulrika
Norin, Nina Greilert
Rihani, Ali
Ujvari, Dorina
Ning, Frank Chenfei
Klingstroem, Jonas
Havervall, Sebastian
Aberg, Mikael
Blom, Kim
Alm, Jessica J.
Thalin, Charlotte
LANCET REGIONAL HEALTH-EUROPE, 2024, 38
[46] SARS-CoV-2 seroprevalence among healthcare workers in a highly vaccinated Japanese medical center from 2020-2023
Yan, Yan
Ito, Kanami
Fukuda, Hiroshi
Nojiri, Shuko
Urasaki, Wataru
Yamamoto, Takamasa
Horiuchi, Yuki
Hori, Satoshi
Takahashi, Kazuhisa
Naito, Toshio
Tabe, Yoko
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
[47] Seroprevalence of Antibodies Against SARS-CoV-2 Among Health Care Workers in Mumbai, India
Kumar, Nishant
Bhartiya, Shibal
Desai, Shashank
Mutha, Amit
Beldar, Amit
Singh, Tarundeep
ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH, 2021, 33 (01) : 126 - 128
[48] Seroprevalence of SARS-CoV-2 antibodies among Japanese healthcare workers from 2020 to 2022 as assayed by two commercial kits
Yan, Yan
Saito, Kaori
Naito, Toshio
Ito, Kanami
Nojiri, Shuko
Horiuchi, Yuki
Deshpande, Gautam A.
Yokokawa, Hirohide
Tabe, Yoko
SCIENTIFIC REPORTS, 2024, 14 (01)
[49] SARS-CoV-2 Exposure and Seroprevalence of SARS-CoV-2 Antibodies among Medical Students in the First Phase of the Pandemic 2020-2021
Landmesser, Patricia
Weissbrich, Benedikt
Peter-Kern, Martina
Krone, Manuel
Liese, Johannes
Streng, Andrea
GESUNDHEITSWESEN, 2024, 86 (04) : 311 - 314
[50] Prevalences of SARS-CoV-2 RNA and anti-SARS-CoV-2 among at-risk populations in Chiang Mai and Lamphun provinces, Thailand, during November 2020-January 2021
Takalay, Siriluk
Ngo-Giang-Huong, Nicole
Kongnim, Wanlee
Mongkolwat, Paporn
Phoseng, Porntip
Wangsaeng, Nantawan
Hongjaisee, Sayamon
Butr-Indr, Bordin
Tragoolpua, Khajornsak
Jourdain, Gonzague
Pornprasert, Sakorn
Khamduang, Woottichai
PLOS ONE, 2022, 17 (02):

← 1 2 3 4 5 →